A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease-Reference-Cited by-同舟云学术

A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. Oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease

Published:2008 Issue:6 Volume:58 Page:1810-1822
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis Rheum

Author:

Postlethwaite Arnold E.,Wong Weng Kee,Clements Philip,Chatterjee Soumya,Fessler Barri J.,Kang Andrew H.,Korn Joseph,Mayes Maureen,Merkel Peter A.,Molitor Jerry A.,Moreland Larry,Rothfield Naomi,Simms Robert W.,Smith Edwin A.,Spiera Robert,Steen Virginia,Warrington Kenneth,White Barbara,Wigley Frederick,Furst Daniel E.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Reference38 articles.

1. IMMUNOPATHOGENESIS OF SYSTEMIC SCLEROSIS

2. Sequential dermal microvascular and perivascular changes in the development of scleroderma

3. Lymphocytes in the skin of patients with progressive systemic sclerosis

4. Fibrosing alveolitis in systemic sclerosis: increase in memory T-cells in lung interstitium

5. Cellular infiltrates in scleroderma skin

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Optimizing oral immune tolerance to Type II collagen in patients with rheumatoid arthritis: The importance of dose, interfering medication and genetics;The American Journal of the Medical Sciences;2024-10

2. Testing Homogeneity of Proportion Ratios for Stratified Bilateral Correlated Data;Mathematical and Computational Applications;2024-03-22

3. EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening;Journal of Experimental & Clinical Cancer Research;2024-01-10

4. EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening;2023-10-09

5. Role of rituximab in the treatment of systemic sclerosis: A literature review;Modern Rheumatology;2023-04-13